The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 40, Issue 3, 2013, Pages 327-342

  Westerhout, Joost ^a   Smeets, Jean ^b   Danhof, Meindert ^a   De Lange, Elizabeth C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LAPandP Consultants BV   (Netherlands)

Author keywords

Blood brain barrier; Brain extracellular fluid; Cerebrospinal fluid; P glycoprotein; Pharmacokinetics; Systems based pharmacokinetic modeling

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; QUINIDINE; TARIQUIDAR;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG TRANSPORT; EXTRACELLULAR FLUID; IN VIVO STUDY; MALE; MATHEMATICAL MODEL; MICRODIALYSIS; NONHUMAN; PASSIVE TRANSPORT; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; EXTRACELLULAR FLUID; MALE; MICRODIALYSIS; MODELS, NEUROLOGICAL; P-GLYCOPROTEIN; QUINIDINE; QUINOLINES; RATS; RATS, WISTAR; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84878757924     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-013-9314-4     Document Type: Article

References (80)

1. De Lange ECM, de Boer AG, Breimer DD (2000) Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Del Rev 45:125-148
2. Hammarlund-Udenaes M (2009) Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 106:215-220
3. De Lange ECM, Danhof M, de Boer AG, Breimer DD (1997) Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Rev 25:27-49
4. Hammarlund-Udenaes M, Bredberg U, Fridén M (2009) Methodologies to assess brain drug delivery in lead optimization. Curr Top Med Chem 9:148-162
5. Westerhout J, Danhof M, de Lange ECM (2011) Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci 100:3577-3593
6. Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding of CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338
7. Maurer TS, DeBartolo DB, Tess DA, Scott D (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181
8. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J (2006) Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos 34:1443-1447
9. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M (2009) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787-793
10. Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M (2009) Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52:6233-6243
11. Lee G, Dallas S, Hong M, Bendayan R (2001) Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 53:569-596
12. De Lange ECM, Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetic to predict brain target concentrations in the clinical setting. Implications of the barriers between blood and brain. Clin Pharmacokinet 41:691-703
13. Shen DD, Artru AA, Adkison KK (2004) Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Del Rev 56:1825-1857
14. Lin JH (2008) CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab 9:46-59
15. Mayer S, Maickel RP, Brodie BB (1959) Kinetics of penetration of drugs and other foreign compounds into cerebrospinal fluid and brain. J Pharmacol Exp Ther 127:205-211
16. Oldendorf WH (1974) Lipid solubility and drug penetration of the blood-brain barrier. Proc Soc Exp Biol Med 147:813-815
17. Betz AL, Goldstein GW (1986) Specialized properties and solute transport in brain capillaries. Annu Rev Physiol 48:241-250
18. Keep RF, Jones HC (1990) A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Dev Brain Res 56:47-53
19. Danhof M, de Jongh J, de Lange ECM, Della Pasqua OE, Ploeger BA, Voskuyl RA (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357-400
20. Westerhout J, Ploeger B, Smeets J, Danhof M, de Lange ECM (2012) Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J 14:543-553
21. Bendayan R, Ronaldson PT, Gingras D, Bendayan M (2006) In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 54:1159-1167
22. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D (1999) Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 96:3900-3905
23. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502
24. Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, van Deemter L, Smit JJM, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P (1997) Normal viability and altered pharmacogenetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad USA 94:4028-4033
25. Schinkel AH (1999) P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Del Rev 36:179-194
26. Wijnholds J, de Lange ECM, Scheffer GL, van den Berg D-J, Mol CAAM, van der Valk M, Schinkel AH, Scheper RJ, Breimer DD, Borst P (2000) Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 105:279-285
27. 4) transfer from CSF to choroid plexus and ventricular brain regions in rabbit: contributory role of P-glycoprotein and organic anion transporting polypeptides. Brain Res 1181:44-50
28. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, Sugiyama Y (1997) P-glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther 283:574-580
29. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CECA, Kasman IN, LaPerle J, Liu JH, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/1b knockout mouse model. Drug Metab Dispos 33:165-174
30. Varma MVS, Panchagnula R (2005) pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ. J Pharm Sci 94:2632-2643
31. Sziráki I, Erdo F, Beéry E, Molnar PM, Fazakas C, Wilhelm I, Makai I, Kis E, Herédi-Szabó K, Abonyi T, Krizbai I, Tóth GK, Krajcsi P (2011) Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study. J Biomol Screen 16:886-894
32. Syvänen S, Schenke M, van den Berg D-J, Voskuyl RA, de Lange ECM (2012) Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry - a study in rats subjected to status epilepticus by kainate. AAPS J 14:87-96
33. Fox E, Bates SE (2007) Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 7:447-459
34. Kurnik D, Sofowora GG, Donahue JP, Nair UB, Wilkinson GR, Wood AJJ, Muszkat M (2008) Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein. Anesthesiology 109:1092-1099
35. Ståhle L, Segersvärd S, Ungerstedt U (1991) A comparison between three methods for estimation of extracellular concentrations of exogenous and endogenous compounds by microdialysis. J Pharmacol Methods 25:41-52
36. Scheller D, Kolb J (1991) The internal reference technique in microdialysis: a practical approach to monitoring dialysis efficiency and to calculating tissue concentration from dialysate samples. J Neurosci Methods 40:31-38
37. Harashima H, Sawada Y, Sugiyama Y, Iga T, Hanano M (1985) Analysis of nonlinear tissue distribution of quinidine in rats by physiologically based pharmacokinetics. J Pharmacokinet Biopharm 13:425-440
38. Thorne RG, Hrabětová S, Nicholson C (2004) Diffusion of epidermal growth factor in rat brain extracellular space measured by integrative optical imaging. J Neurophysiol 92:3471-3481
39. Cserr HF, Cooper DN, Suri PK, Patlak CS (1981) Efflux of radiolabeled polyethylene glycols and albumin from rat brain. Am J Physiol 240:F319-F328
40. Bass NH, Lundborg P (1973) Postnatal development of bulk flow in the cerebrospinal fluid system of the albino rat: clearance of carboxyl-[14C]inulin after intrathecal infusion. Brain Res 52:323-332
41. Condon P, Patterson J, Wyper D, Hadley D, Grant R, Teasdale G, Rowan J (1986) Use of magnetic resonance imaging to measure intracranial cerebrospinal fluid volume. Lancet 327:1355-1357
42. Kohn MI, Tanna NK, Herman GT, Resnick SM, Mozley PD, Gur RE, Alavi A, Zimmerman RA, Gur RC (1991) Analysis of brain and cerebrospinal fluid volumes with MR imaging. Part I. Methods, reliability, and validation. Radiology 178:115-122
43. Levinger IM (1971) The cerebral ventricles of the rat. J Anat 108:447-451
44. Robertson EG (1949) Developmental defects of the cisterna magna and dura mater. J Neurol Neurosurg Psychiatry 12:39-51
45. Adam R, Greenberg JO (1978) The mega cisterna magna. J Neurosurg 48:190-192
46. Abbott NJ (2004) Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int 45:545-552
47. Cserr HF (1965) Potassium exchange between cerebrospinal fluid, plasma, and brain. Am J Physiol 209:1219-1226
48. Cox EH, Veyrat-Follet C, Beal SL, Fuseau E, Kenkare S, Sheiner LB (1999) A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron. J Pharmacokinet Biopharm 27:625-644
49. Duffull SB, Aarons L (2000) Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. Eur J Pharm Sci 10:275-284
50. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171-192
51. Syvänen S, Xie R, Sahin S, Hammarlund-Udenaes M (2006) Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm Res 23:705-717
52. Lee HB, Blaufox MD (1985) Blood volume in the rat. J Nucl Med 26:72-76
53. Ball WJ Jr, Tse-Eng D, Wallick ET, Bilezikian JP, Schwartz A, Butler VP (1981) Effect of quinidine on the digoxin receptor in vitro. J Clin Invest 68:1065-1074
54. +-ATPase catalytic polypeptide in mouse choroid plexus. J Histochem Cytochem 34:189-195
55. Brown PD, Davies SL, Speake T, Millar ID (2004) Molecular mechanisms of cerebrospinal fluid production. Neuroscience 129:957-970
56. Stein WD, Cardarelli C, Pastan I, Gottesman MM (1994) Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol Pharmacol 45:763-772
57. Sun H, Bungay PM, Elmquist WF (2001) Effect of capillary efflux transport inhibition on the determination of probe recovery during in vivo microdialysis in the brain. J Pharmacol Exp Ther 297:991-1000
58. ® to experimentally determined values. Int J Pharm 294:185-192
59. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61:749-758
60. 11C-Verapamil and PET. J Nucl Med 49:1328-1335
61. 11C]Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus. BMC Med Imaging. doi: 10.1186/1471-2342-11-1
62. Kakee A, Terasaki T, Sugiyama Y (1996) Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 277:1550-1559
63. Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y (2011) Quantitative evaluation of the impact of active efflux by P-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentrations as a surrogate. J Pharmacol Exp Ther 339:935-944
64. Van Montfoort JE, Müller M, Groothuis GMM, Meijer DKF, Koepsell H, Meier PJ (2001) Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther 298:110-115
65. Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Wah Yee S, Zamek-Gliszczyncski MJ, Zhang L (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236
66. Lin C-J, Tai Y, Huang M-T, Tsai Y-F, Hsu H-J, Tzen K-Y, Liou H-H (2010) Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. J Neurochem 114:717-727
67. Choudhuri S, Cherrington NJ, Li N, Klaassen CD (2003) Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab Dispos 31:1337-1345
68. De Lange ECM (2013) Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn. doi: 10.1007/s10928-013-9301-9
69. De Lange ECM (2013) The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS, theme issue "Technique and Research Protocols to study Brain Barriers in Vivo, in Vitro and in Situ". Ed B. Engelhardt, D. Stamirovic, and EC de Lange. Fluids Barriers CNS 10:12. doi: 10.1186/2045-8118-10-12
70. Higgins CF, Gottesman MM (1992) Is the multidrug transporter a flippase? Trends Biochem Sci 17:18-21
71. Sharom FJ (1997) The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 160:161-175
72. Sharom FJ (2006) Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem Cell Biol 84:979-992
73. Pardridge WM, Golden PL, Kang YS, Bickel U (1997) Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem 68:1278-1285
74. Declèves X, Regina A, Laplanche JL, Roux F, Boval B, Launay JM, Scherrmann JM (2000) Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes. J Neurosci Res 60:594-602
75. Golden PL, Pardridge WM (2000) Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain. Cell Mol Neurobiol 20:165-181
76. Seegers U, Potschka H, Löscher W (2002) Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res 51:257-268
77. Seegers U, Potschka H, Löscher W (2002) Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia 43:675-684
78. Volk HA, Potschka H, Löscher W (2005) Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem 53:517-531
79. Kielbasa W, Kalvass JC, Stratford R (2009) Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. Drug Metab Dispos 37:137-142
80. Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A (2008) On the rate and extent of drug delivery to the brain. Pharm Res 25:1737-1750